Celltrion Biosimilar Is Latest To Run Into GMP Compliance Concerns
• By Joanne S. Eglovitch
Generate a summary of this article
Listen to this article
An FDA inspection uncovered a wide-ranging list of GMP problems at biopharmaceutical manufacturer Celltrion in South Korea. Among some of the problems that inspectors found were mold on walls in sterile areas, operators leaning over sterile areas with bare hands and arms, and employees using shared passwords. A resulting Form 483 report is the latest in a number of recent enforcement actions targeting proposed biosimilar drugs.
FDA investigators found a multitude of GMP problems at Celltrion Inc. including lax contamination controls and inadequate investigation into complaints. This action is the latest of several GMP compliance challenges confronting manufacturers launching biosimilars in recent months.
Investigators sent a Form 483 report of inspectional observations June 2 after an inspection of the Incheon, South...
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
The UK regulator approved 16 medicines containing a new active substance in the first half of this year, while the European Commission issued marketing authorizations for 20 NAS-containing drugs.
Joint clinical assessment reports must be descriptive rather than reach definitive conclusions, and must not interfere with national decision making processes, according to new EU guidance.
Joint clinical assessment reports must be descriptive rather than reach definitive conclusions, and must not interfere with national decision making processes, according to new EU guidance.